NCT03953898View on ClinicalTrials.gov

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

January 16, 2024

Study Completion Date

February 20, 2026

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

DRUG

Olaparib

Given PO

Trial Locations (11)

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

27012

Wake Forest University at Clemmons, Clemmons

27157

Wake Forest University Health Sciences, Winston-Salem

28659

Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33146

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

33324

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation

33442

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

06520

Yale University, New Haven

03756

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH